Treatment with Histone Deacetylase Inhibitors Creates 'BRCAness' and Sensitizes Human Triple Negative Breast Cancer Cells to PARP Inhibitors and Cisplatin

被引：6
|
作者：
Bhalla, K. N. [1 ]
Rao, R. [1 ]
Sharma, P. [1 ]
Das Gupta, S. [1 ]
Chauhan, L. [1 ]
Stecklein, S. [1 ]
Fiskus, W. [1 ]
机构：
[1] Univ Kansas, Ctr Canc, Kansas City, KS USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-S3-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S3-7
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
    Ha, Kyungsoo
    Fiskus, Warren
    Choi, Dong Soon
    Bhaskara, Srividya
    Cerchietti, Leandro
    Devaraj, Santhana G. T.
    Shah, Bhavin
    Sharma, Sunil
    Chang, Jenny C.
    Melnick, Ari M.
    Hiebert, Scott
    Bhalla, Kapil N.
    ONCOTARGET, 2014, 5 (14) : 5637 - 5650
  • [2] Histone deacetylase inhibitors sensitize cancer stem cells to PARP inhibitors in triple-negative breast cancer
    Liu, Yajing
    Martin-Trevino, Rachel
    Shang, Li
    Davis, April
    Wicha, Max
    Liu, Suling
    Burness, Monika
    CANCER RESEARCH, 2015, 75
  • [3] The response of histone deacetylase inhibitors in triple negative breast cancer
    Alzoubi, Madlin
    Nguyen, Khoa
    Burks, Hope
    Hebert, Katherine
    Cheng, Thomas
    Matossian, Margarite
    Wright, Maryl
    Collins-Burow, Bridgette
    Burow, Matthew
    CANCER RESEARCH, 2022, 82 (04)
  • [4] Targeting triple negative breast cancer with histone deacetylase inhibitors
    Fedele, Palma
    Orlando, Laura
    Cinieri, Saverio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (11) : 1199 - 1206
  • [5] Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4
    Gu, Zhangyuan
    Ye, Fugui
    Luo, Hong
    Li, Xiaoguang
    Gong, Yue
    Mao, Shiqi
    Jia, Xiaoqing
    Han, Xiangchen
    Han, Boyue
    Fu, Yun
    Cheng, Xiaolin
    Li, Jiejing
    Shao, Zhiming
    Wen, Peizhen
    Hu, Xin
    Zhuang, Zhigang
    JOURNAL OF BIOMEDICAL SCIENCE, 2025, 32 (01)
  • [6] PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Jill J. J. Geenen
    Sabine C. Linn
    Jos H. Beijnen
    Jan H. M. Schellens
    Clinical Pharmacokinetics, 2018, 57 : 427 - 437
  • [7] PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Geenen, Jill J. J.
    Linn, Sabine C.
    Beijnen, Jos H.
    Schellens, Jan H. M.
    CLINICAL PHARMACOKINETICS, 2018, 57 (04) : 427 - 437
  • [8] Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells
    Eskiler, Gamze Guney
    Ozman, Zeynep
    Haciefendi, Ayten
    Cansaran-Duman, Demet
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2023, 396 (05) : 1031 - 1041
  • [9] Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells
    Gamze Guney Eskiler
    Zeynep Ozman
    Ayten Haciefendi
    Demet Cansaran-Duman
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396 : 1031 - 1041
  • [10] Bortezomib Induced BRCAness Sensitizes Multiple Myeloma Cells to PARP Inhibitors
    Neri, Paola
    Ren, Li
    Gratton, Kathy
    Stebner, Erin
    Owen, Carolyn J.
    Duggan, Peter
    Mansoor, Adnan
    Stewart, Douglas A.
    Bahlis, Nizar J.
    BLOOD, 2010, 116 (21) : 346 - 346
12345